KINIKSA PHARMACEUTICALS, LTD.

Analyst Reco. Kiniksa Pharmaceuticals, Ltd.

Equities

KNSA

BMG5269C1010

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
19.04 ^USD	-0.05%		-1.70%	+8.55%

May. 14	Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM
Apr. 23	Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Wedbush Adjusts Kiniksa Pharmaceuticals' PT to $30 From $28, Maintains Outperform Rating	Apr. 03	MT
Wedbush Lifts Kiniksa Pharmaceuticals' PT to $25 From $23 Ahead of Planned Q1 Reporting of Initial Data on KPL-404; Maintains Outperform Rating	Jan. 02	MT
Wedbush Adjusts Kiniksa Pharmaceuticals Price Target to $23 From $21, Maintains Outperform Rating	23-07-25	MT
Wedbush Raises Kiniksa Pharmaceuticals Price Target to $21 From $20, Maintains Outperform Rating	23-05-02	MT
JPMorgan Adjusts Kiniksa Pharmaceuticals' Price Target to $20 From $19, Keeps Overweight Rating	23-03-09	MT
Wedbush Lowers Kiniksa Pharmaceuticals' Price Target to $20 From $26, Adjusts Commercial Ramp Assumptions for Arcalyst; Keeps Outperform Rating	23-03-01	MT
Wedbush Lifts Price Target on Kiniksa Pharmaceuticals to $26 From $25, Keeps Outperform Rating	22-11-02	MT
Wedbush Lifts Price Target for Kiniksa Pharmaceuticals to $25 From $24, Maintains Outperform Rating	22-05-03	MT
Wedbush Lowers Price Target for Kiniksa Pharmaceuticals to $24 From $28, Maintains Outperform Rating	22-02-22	MT
Wedbush Lifts Price Target on Kiniksa Pharmaceuticals to $28 From $25.91; Outperform Rating Kept	22-01-11	MT
BofA Securities Adjusts Kiniksa Pharmaceuticals' Price Target to $34 From $37, Reiterates Buy Rating	21-12-29	MT
JPMorgan Adjusts Price Target on Kiniksa Pharmaceuticals to $27 From $30, Reiterates Overweight Rating	21-11-02	MT
Wedbush Lifts Kiniksa Pharmaceuticals' Price Target to $26 From $24; Outperform Rating Kept	21-11-02	MT
KINIKSA PHARMACEUTICALS : Wedbush Cuts Price Target on Kiniksa Pharmaceuticals to $24 From $32, Citing Vixarelimab Launch Timeline; Outperform Rating Kept	21-08-04	MT
KINIKSA PHARMACEUTICALS : Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $32 From $35 on Estimated Mavrilimumab Launch Date; Outperform Rating Kept	21-06-09	MT
KINIKSA PHARMACEUTICALS : Evercore ISI Starts Kiniksa Pharmaceuticals at Outperform with $25 Price Target	20-11-24	MT
KINIKSA PHARMACEUTICALS : Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $35 From $38, Keeps Outperform Rating	20-11-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer